Y
Yao Huang
Publications - 5
Citations - 170
Yao Huang is an academic researcher. The author has contributed to research in topics: Lixisenatide & Type 2 diabetes. The author has an hindex of 3, co-authored 5 publications receiving 111 citations.
Papers
More filters
Journal ArticleDOI
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Marcel H. A. Muskiet,Lennart Tonneijck,Yao Huang,Minzhi Liu,Aramesh Saremi,Hiddo J.L. Heerspink,Daniël H. van Raalte +6 more
TL;DR: An exploratory analysis of ELIXA investigated percentage change in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) according to prespecified albuminuria status at baseline and associated lixisenatide was associated with a reduced risk of new-onset macroalbuminuria.
Journal ArticleDOI
Lixisenatide and Renal Outcomes in Patients with Type 2 Diabetes—A Post-Hoc Analysis of the ELIXA Trial
Marcel H. A. Muskiet,Lennart Tonneijck,Yao Huang,Minzhi Liu,Aramesh Saremi,Hiddo J.L. Heerspink,Daniël H. van Raalte +6 more
TL;DR: In pts with T2D and a recent acute coronary event, Lixi reduced UACR progression in pts with BL micro- or macro albuminuria and was associated with lower incidence of macroalbuminuria beyond glycemic control.
Journal ArticleDOI
Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
TL;DR: iGlarLixi lowered glycated haemoglobin more versus iGlar regardless of T1D duration, with benefit retained even among patients with the longest T2D duration.
Journal ArticleDOI
Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L
TL;DR: Shorter-acting GLP-1RA like lixisenatide have insulin-independent effects, which may benefit patients with longer T2D duration and more β-cell dysfunction, with greatest difference in those with longest duration.